These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

530 related items for PubMed ID: 20686466

  • 1. Inflammatory bowel disease, irritable bowel syndrome, or what?: A challenge to the functional-organic dichotomy.
    Long MD, Drossman DA.
    Am J Gastroenterol; 2010 Aug; 105(8):1796-8. PubMed ID: 20686466
    [Abstract] [Full Text] [Related]

  • 2. Irritable bowel syndrome-type symptoms in patients with inflammatory bowel disease: a real association or reflection of occult inflammation?
    Keohane J, O'Mahony C, O'Mahony L, O'Mahony S, Quigley EM, Shanahan F.
    Am J Gastroenterol; 2010 Aug; 105(8):1788, 1789-94; quiz 1795. PubMed ID: 20389294
    [Abstract] [Full Text] [Related]

  • 3. Faecal S100A12 as a non-invasive marker distinguishing inflammatory bowel disease from irritable bowel syndrome.
    Kaiser T, Langhorst J, Wittkowski H, Becker K, Friedrich AW, Rueffer A, Dobos GJ, Roth J, Foell D.
    Gut; 2007 Dec; 56(12):1706-13. PubMed ID: 17675327
    [Abstract] [Full Text] [Related]

  • 4. [Calprotectin in feces a well-documented marker of gastrointestinal inflammation. Indicates disease intensity--normalization of values predict mucosal healing].
    Lasson A.
    Lakartidningen; 2007 Dec; 107(43):2645-9. PubMed ID: 21137533
    [No Abstract] [Full Text] [Related]

  • 5. Quality of life in inflammatory bowel disease in remission: the impact of IBS-like symptoms and associated psychological factors.
    Simrén M, Axelsson J, Gillberg R, Abrahamsson H, Svedlund J, Björnsson ES.
    Am J Gastroenterol; 2002 Feb; 97(2):389-96. PubMed ID: 11866278
    [Abstract] [Full Text] [Related]

  • 6. Faecal calprotectin: a new marker for Crohn's disease?
    Wassell J, Dolwani S, Metzner M, Losty H, Hawthorne A.
    Ann Clin Biochem; 2004 May; 41(Pt 3):230-2. PubMed ID: 15117438
    [Abstract] [Full Text] [Related]

  • 7. Faecal calprotectin as a novel biomarker for differentiating between inflammatory bowel disease and irritable bowel syndrome.
    Chang MH, Chou JW, Chen SM, Tsai MC, Sun YS, Lin CC, Lin CP.
    Mol Med Rep; 2014 Jul; 10(1):522-6. PubMed ID: 24788223
    [Abstract] [Full Text] [Related]

  • 8. Characterization of IBS-like symptoms in patients with ulcerative colitis in clinical remission.
    Jonefjäll B, Strid H, Ohman L, Svedlund J, Bergstedt A, Simren M.
    Neurogastroenterol Motil; 2013 Sep; 25(9):756-e578. PubMed ID: 23731196
    [Abstract] [Full Text] [Related]

  • 9. Fecal leukocyte proteins in inflammatory bowel disease and irritable bowel syndrome.
    Silberer H, Küppers B, Mickisch O, Baniewicz W, Drescher M, Traber L, Kempf A, Schmidt-Gayk H.
    Clin Lab; 2005 Sep; 51(3-4):117-26. PubMed ID: 15819166
    [Abstract] [Full Text] [Related]

  • 10. Multigene analysis can discriminate between ulcerative colitis, Crohn's disease, and irritable bowel syndrome.
    von Stein P, Lofberg R, Kuznetsov NV, Gielen AW, Persson JO, Sundberg R, Hellstrom K, Eriksson A, Befrits R, Ost A, von Stein OD.
    Gastroenterology; 2008 Jun; 134(7):1869-81; quiz 2153-4. PubMed ID: 18466904
    [Abstract] [Full Text] [Related]

  • 11. Accuracy of four fecal assays in the diagnosis of colitis.
    Schoepfer AM, Trummler M, Seeholzer P, Criblez DH, Seibold F.
    Dis Colon Rectum; 2007 Oct; 50(10):1697-706. PubMed ID: 17762964
    [Abstract] [Full Text] [Related]

  • 12. Psychological adjustment and autonomic disturbances in inflammatory bowel diseases and irritable bowel syndrome.
    Pellissier S, Dantzer C, Canini F, Mathieu N, Bonaz B.
    Psychoneuroendocrinology; 2010 Jun; 35(5):653-62. PubMed ID: 19910123
    [Abstract] [Full Text] [Related]

  • 13. The functional-organic dichotomy: postinfectious irritable bowel syndrome and inflammatory bowel disease-irritable bowel syndrome.
    Grover M, Herfarth H, Drossman DA.
    Clin Gastroenterol Hepatol; 2009 Jan; 7(1):48-53. PubMed ID: 18848909
    [Abstract] [Full Text] [Related]

  • 14. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices.
    Langhorst J, Elsenbruch S, Koelzer J, Rueffer A, Michalsen A, Dobos GJ.
    Am J Gastroenterol; 2008 Jan; 103(1):162-9. PubMed ID: 17916108
    [Abstract] [Full Text] [Related]

  • 15. The prevalence of irritable bowel syndrome-type symptoms in inflammatory bowel disease patients in remission.
    Hoekman DR, Zeevenhooven J, D'Haens GR, Benninga MA.
    Eur J Gastroenterol Hepatol; 2017 Sep; 29(9):1086-1090. PubMed ID: 28639969
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Faecal markers of gastrointestinal inflammation.
    Sherwood RA.
    J Clin Pathol; 2012 Nov; 65(11):981-5. PubMed ID: 22813730
    [Abstract] [Full Text] [Related]

  • 18. Diagnostic value of calprotectin in irritable bowel syndrome and in inflammatory bowel disease.
    Grad C, David L, Portincasa P, Dumitraşcu DL.
    Rom J Intern Med; 2012 Nov; 50(1):3-6. PubMed ID: 22788087
    [Abstract] [Full Text] [Related]

  • 19. Faecal calprotectin concentrations in gastrointestinal diseases.
    Wang S, Wang Z, Shi H, Heng L, Juan W, Yuan B, Wu X, Wang F.
    J Int Med Res; 2013 Aug; 41(4):1357-61. PubMed ID: 23723365
    [Abstract] [Full Text] [Related]

  • 20. [Irritable bowel syndrome and inflammatory bowel disease: Is there a connection?].
    Mearin F, Perelló A, Balboa A.
    Gastroenterol Hepatol; 2009 May; 32(5):364-72. PubMed ID: 19442413
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.